RBC Capital lowered the firm’s price target on Bausch + Lomb to $20 from $21 and keeps an Outperform rating on the shares ahead of its Q3 results. The quarter will continue to be influenced by FX headwinds, which have worsened since the company reported Q2 earnings, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BLCO:
- Bausch + Lomb price target lowered to $18.50 from $20 at Morgan Stanley
- Bausch + Lomb price target lowered to $21 from $22 at H.C. Wainwright
- Eli Lilly deal for Point puts radiopharma names in spotlight
- Novartis weighing sale of assets from radiopharma unit, Bloomberg says
- Bausch + Lomb resumed with an Outperform at Evercore ISI
